This document discusses future research priorities for tuberculosis control post-2015. It outlines the rationale for developing a new global TB strategy after 2015, including addressing challenges like case detection, TB/HIV co-infection, and drug-resistant TB. Six categories of TB research are identified: epidemiology, fundamental research, diagnostics, treatment, vaccines, and operational research. Key areas for future research include developing new diagnostics, drugs, vaccines, and optimizing case detection and treatment delivery. Funding for TB research needs to increase to develop innovative tools and strategies to work towards a world free of TB.
Standards for TB care in India, RNTCP challenges: India, Maharashtra & Mumbai...Amol Patil
This presentation contains TB statistics- Global, India, Maharashtra and Mumbai till 2015.
Details of TB control strategies will be covered in Subsequent parts.
After the successful NSP 2017-2025,Goi is lauching NSP 2017-2025 for elimination of TB on 24th march( World TB day ) 2017. Module is on MOHFW site but i have try to keep it brief,hope its ll be useful specially for academic and administrative purposes.
Standards for TB care in India, RNTCP challenges: India, Maharashtra & Mumbai...Amol Patil
This presentation contains TB statistics- Global, India, Maharashtra and Mumbai till 2015.
Details of TB control strategies will be covered in Subsequent parts.
After the successful NSP 2017-2025,Goi is lauching NSP 2017-2025 for elimination of TB on 24th march( World TB day ) 2017. Module is on MOHFW site but i have try to keep it brief,hope its ll be useful specially for academic and administrative purposes.
RNTCP guidelines for tuberculosis management: Extended versionRxVichuZ
This presentation is an extension of the already made presentation before, that deals with RNTCP guidelines for some special aspects encountered during tuberculosis management, other than management of individual diagnoses alone.
Have a look!
INTRODUCTION
HISTORY OF TUBERCULOSIS
NATIONAL TB CONTROL PROGRAMME
REVISED NATIONAL TB CONTROL PROGRAMME I (RNTCP- I)
DIRECTLY OBSERVED TREATMENT SHORT COURSE (DOTS)
STOP TB STRATEGY
REVISED NATIONAL TB CONTROL PROGRAMME II (RNTCP- II)
BACKGROUND FOR NSP (2012-2017)
NATIONAL STRATEGIC PLAN (2012-2017)
END TB STRATEGY
BURDEN OF TB IN INDIA – 2017
NATIONAL STRATEGIC PLAN (2017-2025)
RECENT ADVANCES IN TB CONTROL
Tutorial for beginning graduate students. Some guidelines for composing the research proposal for an MS project. Also presents the perspective of advisor and committee.
Harder-to-treat and more lethal tubercle bacilli continue to emerge across the globe, especially in the African region. Together with HIV, these infectious killers continue to have profound effects on the productive workforce in different countries. The deck is a brief overview of developments in disease management and research, with an emphasis on medications and vaccines.
RNTCP guidelines for tuberculosis management: Extended versionRxVichuZ
This presentation is an extension of the already made presentation before, that deals with RNTCP guidelines for some special aspects encountered during tuberculosis management, other than management of individual diagnoses alone.
Have a look!
INTRODUCTION
HISTORY OF TUBERCULOSIS
NATIONAL TB CONTROL PROGRAMME
REVISED NATIONAL TB CONTROL PROGRAMME I (RNTCP- I)
DIRECTLY OBSERVED TREATMENT SHORT COURSE (DOTS)
STOP TB STRATEGY
REVISED NATIONAL TB CONTROL PROGRAMME II (RNTCP- II)
BACKGROUND FOR NSP (2012-2017)
NATIONAL STRATEGIC PLAN (2012-2017)
END TB STRATEGY
BURDEN OF TB IN INDIA – 2017
NATIONAL STRATEGIC PLAN (2017-2025)
RECENT ADVANCES IN TB CONTROL
Tutorial for beginning graduate students. Some guidelines for composing the research proposal for an MS project. Also presents the perspective of advisor and committee.
Harder-to-treat and more lethal tubercle bacilli continue to emerge across the globe, especially in the African region. Together with HIV, these infectious killers continue to have profound effects on the productive workforce in different countries. The deck is a brief overview of developments in disease management and research, with an emphasis on medications and vaccines.
Module: [LIBR_01]_SIGE XIII_Method Prop to Design Radars
Topic: RESEARCH, DEVELOPMENT & INNOVATION
Subject: A Methodology Proposal to Design Radars - Systems Approach
Article by Antonio Sallum Librelato and Osamu Saotome, presented and published during the XIII SIGE. ITA, 27 a 30 de setembro de 2011.
Scope:
Abstract
I. INTRODUCTION
Motivations for the Systems Concepts Research (SCR) method
II. BRIEF DESCRIPTION OF THE SCR METHOD
Principles of SCR
Phases of the SCR
Purposes of SCR
III. NRA - NEEDS AND REQUIREMENTS ANALYSIS
Purposes of NRA
Steps and Tasks of NRA
IV. SCE - SYSTEMS CONCEPTS EXPLORATION
Purposes of SCE
Steps and Tasks of SCE
V. SCD - SYSTEM CONCEPT DEFINITION
Purposes of SCD
Steps and Tasks of SCD
VI. SRAA - SYSTEMS RISKS AND ASSURANCE ANALYSIS
Purposes of SRAA
Steps and Tasks of SRAA
VII. CONCLUSIONS
REFERENCES
"What Will It Take To Control TB?" Richard Chaisson, MDUWGlobalHealth
Dr. Richard Chaisson, Professor of Medicine, Epidemiology and International Health and Director of the Center for Tuberculosis Research at the Johns Hopkins University in Baltimore was the keynote Jan. 19 as part of the Washington Global Health Discovery Series. His talk was on ""What Will It Take To Control TB?"
Epidemiology is a basic discipline essential to both clinical and community medicines. It also helps to develop the way of thinking about health and disease.
Antibiotic Guardian Birmingham Workshop4 All of Us
Antibiotic resistance is one of the biggest threats facing us today!
European Antibiotic Awareness Day (EAAD) is part of the UK 5 Year Antimicrobial Resistance Strategy 2013 to 2018, which focuses on antibiotics and sets out actions to slow the development and spread of antimicrobial resistance.
This year, to run in line with EAAD; Public Health England has established the Antibiotic Guardian pledge campaign. It calls on everyone in the UK, the public and healthcare community to become antibiotics guardian by choosing one simple pledge about how they will make better use of these vital medicines.
To ensure that the information and knowledge on Antibiotic Stewardship is disseminated to those practising healthcare across the nation, a series of awareness and educational events have been developed. These educational workshop events, to be held in Leeds, Birmingham and London, will provide guidance, resources and information for practitioners on topics associated with antibiotic awareness. The events will provide an opportunity to understand how you and your organisation can support combat the global challenge faced by antibiotic resistance whilst gaining advice, support and resources to inform patients and staff.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Future tb research nhung
1. FUTURE RESEARCH MOVEMENT
FOR TUBERCULOSIS CONTROL
FUTURE RESEARCH MOVEMENT
FOR TUBERCULOSIS CONTROL
A/Prof. Nguyen Viet Nhung, MD., PhD
Vice director, National Lung Hospital, Hanoi, Viet Nam
Deputy Manager, National Tuberculosis control Program
Vice President, Viet Nam Association against TB and Lung Diseases
Regional Green Light Committee - WHO / WPR
2.
3.
4. Looking beyond 2015:
Rationale
At the 65th World Health Assembly in May 2012, Member States called upon WHO to
develop a new post-2015 TB strategy and targets and present this to Member States at
the 67th World Health Assembly in 2014. Some States also urged WHO to start the
formal process through the Executive Board and World Health Assembly in 2013.
5. Start Developing
Draft Global strategy
for TB prevention, treatment and care
post-2015
Dr Malgosia Grzemska
Stop TB Department
World Health Organization
TAG TB/WPRO
Phnom Penh, Cambodia, 23-25 October 2012
6. Moving towards a new approach:
Addressing the most vulnerable
Half a million women and
over 70,000 children die of
TB each year; 10 million
“TB” orphans
Poor, crowded & poorly ventilated
settings
TB linked to HIV infection, malnutrition,
alcohol, drug and tobacco use, diabetes
Half a million women and
over 70,000 children die of
TB each year; 10 million
“TB” orphans
Migrants, prisoners, minorities,
refugees face risks, discrimination
& barriers to care
7. Moving towards a new approach:
Addressing key challenges
Case detection
A third of cases not
diagnosed/reported
TB/HIV co infection
Special challenge in Africa
Multidrug - resistant TB
Special challenge in Eastern
Europe
Bottlenecks for financing of
research and innovation
Case detection
A third of cases not
diagnosed/reported
TB/HIV co infection
Special challenge in Africa
Multidrug - resistant TB
Special challenge in Eastern
Europe
Weak health policies,
systems, financing, and
services
Under-engaged
communities and
providers
8. The way forward:
Expansion with Innovation
• Greater commitment
• Active case finding
• Molecular diagnosis
• Treat all forms of TB
• Treatment of latent TB
• Research and
innovation
• Much greater engagement of
all providers and community
• Much stronger system support
• Social protection
• Whole-of-government
approach
• Major drive for Innovation
More and Better
Stop TB Strategy
• (Enhanced and)
innovative TB
care/DOTS
• Bold policies and
supportive systems
• Intensified research
and innovation
• Greater commitment
• Active case finding
• Molecular diagnosis
• Treat all forms of TB
• Treatment of latent TB
• Research and
innovation
More and
Better DOTS
• Much greater engagement of
all providers and community
• Much stronger system support
• Social protection
• Whole-of-government
approach
• Major drive for Innovation
• (Enhanced and)
innovative TB
care/DOTS
• Bold policies and
supportive systems
• Intensified research
and innovation
Post-2015
TB Strategy
9. Proposed three pillars
Establishing a
new post-2015 strategy
Innovativ
e TB Care
Bold
policies and
supportive
systems Intensified
research
and
innovation
WHOandPartnersSupporttocountries
Surveillance,MonitoringandEvaluation
Intensified
research
and
innovation
WHOandPartnersSupporttocountries
Surveillance,MonitoringandEvaluation
10. Innovative TB Care
Bold policies and
supportive systems
Intensified Research
Vision: A world free of TB
DRAFT Post-2015 TB Strategy
CORE PRINCIPLES:
Government stewardship with adequate financing
Engagement of communities and civil society; Collaboration with private sector
Promotion of human rights, ethics and equity
Adaptation of the strategy and targets at country level
Monitoring and evaluation across all strategy components
Innovative TB Care
Rapid diagnosis and systematic
screening of contacts and other
high-risk populations
Treatment of all forms of TB with
patient support
Management of drug-resistant TB,
TB/HIV and other co-morbidities
Preventive treatment of high-risk
populations
Bold policies and
supportive systems
Policies pursuing a system-wide
approach for integration of TB care in
all health services
Universal Health Coverage with free
TB care and social protection
Regulatory framework including vital
registration, mandatory case-
notification, infection control and
rational use of quality-assured drugs
Whole-of-government approach to
addressing social determinants of TB
including poverty reduction, food
security, healthy living and working
conditions
Intensified Research
Discovery, development and rapid
uptake of new diagnostics, drugs
and vaccines
Research to optimize
implementation and adopt
innovations
Sept 2012
11. Six categories of
TB Research
1. Epidemiology
2. Fundamental research
3. Diagnostics
4. Treatment
5. Vaccines
6. Operational and
public health research
1. Epidemiology
2. Fundamental research
3. Diagnostics
4. Treatment
5. Vaccines
6. Operational and
public health research
12. 1. Epidemiology
– Determine the burden of TB
– Understand variations in the dynamics of TB in
different settings and identify the social and
biological drivers of M. tuberculosis transmission
at population level
2. Fundamental research
– Characterize human TB by modern biochemical,
clinical and epidemiological approaches
– Better understand the host–pathogen interaction
– Use ‘discovery science’ to identify biomarkers
that can better differentiate the stages of the
disease spectrum.
1. Epidemiology
– Determine the burden of TB
– Understand variations in the dynamics of TB in
different settings and identify the social and
biological drivers of M. tuberculosis transmission
at population level
2. Fundamental research
– Characterize human TB by modern biochemical,
clinical and epidemiological approaches
– Better understand the host–pathogen interaction
– Use ‘discovery science’ to identify biomarkers
that can better differentiate the stages of the
disease spectrum.
13. 3. Diagnostics
– Evaluate biomarkers identified in fundamental
studies for use as diagnostic tools
– Design and validate a set of tools for diagnosis of
active drug-sensitive and drug-resistant TB and
latent TB infection that are feasible and applicable
at various health-care levels in high-burden settings
– Improve existing diagnostic tests for active drug-
sensitive and drug-resistant TB and latent TB
infection at various health-care levels in high-
burden settings
– Evaluate new diagnostic tools, and conduct
demonstration studies, followed by evaluation of
the programmatic impact of all diagnostic tools
3. Diagnostics
– Evaluate biomarkers identified in fundamental
studies for use as diagnostic tools
– Design and validate a set of tools for diagnosis of
active drug-sensitive and drug-resistant TB and
latent TB infection that are feasible and applicable
at various health-care levels in high-burden settings
– Improve existing diagnostic tests for active drug-
sensitive and drug-resistant TB and latent TB
infection at various health-care levels in high-
burden settings
– Evaluate new diagnostic tools, and conduct
demonstration studies, followed by evaluation of
the programmatic impact of all diagnostic tools
14. 4. Treatment
– Develop new drugs and treatment strategies
– Develop a shorter regimen for drug-susceptible TB
that can be used in combination with HIV
treatment
– Develop a safer, more efficacious, shorter regimen
for drug-resistant TB that is compatible with HIV
treatment
– Develop safe, reliable, user-friendly drug regimens
suitable for all forms of TB in children and
compatible with HIV treatment
– Develop safer, more effective, shorter regimens for
TB infected individuals
– Develop safer, shorter, highly effective regimens
for drug-susceptible and drug-resistant latent TB
infection that are compatible with HIV treatment
and suitable for children
4. Treatment
– Develop new drugs and treatment strategies
– Develop a shorter regimen for drug-susceptible TB
that can be used in combination with HIV
treatment
– Develop a safer, more efficacious, shorter regimen
for drug-resistant TB that is compatible with HIV
treatment
– Develop safe, reliable, user-friendly drug regimens
suitable for all forms of TB in children and
compatible with HIV treatment
– Develop safer, more effective, shorter regimens for
TB infected individuals
– Develop safer, shorter, highly effective regimens
for drug-susceptible and drug-resistant latent TB
infection that are compatible with HIV treatment
and suitable for children
15. 5. Vaccines
– Conduct fundamental research as a basis for the
development of effective TB vaccines
– Conduct research and clinical testing to better
understand the safety and efficacy of BCG and
candidate vaccines
– Develop standardized assays and find
biomarkers for use in clinical trials to identify
correlates of protection
– Develop new pre- and post-exposure vaccines,
new adjuvants and new delivery platforms
– Improve and standardize preclinical assays to
evaluate immunogenicity and potential
protective efficacy of new TB vaccines
– Improve and standardize testing of TB vaccines
in clinical trials
5. Vaccines
– Conduct fundamental research as a basis for the
development of effective TB vaccines
– Conduct research and clinical testing to better
understand the safety and efficacy of BCG and
candidate vaccines
– Develop standardized assays and find
biomarkers for use in clinical trials to identify
correlates of protection
– Develop new pre- and post-exposure vaccines,
new adjuvants and new delivery platforms
– Improve and standardize preclinical assays to
evaluate immunogenicity and potential
protective efficacy of new TB vaccines
– Improve and standardize testing of TB vaccines
in clinical trials
16. 6. Operational and public health research
– Improve TB case detection and diagnosis
– Investigate methods to improve access to treatment and treatment
delivery for drug-sensitive and drug-resistant TB
– Institute sustainable collaboration with all private and public
providers of TB care and control
– Address priority operational research questions at global, regional or
national level to improve implementation of collaborative TB and
HIV activities, and also in respect of other diseases or conditions in
which the risk for TB is increased
– Design collaborative activities in other disease programmes or
situations in which TB risk is increased
– Investigate methods to encourage community participation, to
increase the effectiveness of all interventions (e.g. case-finding,
access to treatment and care delivery)
– Optimize infection control to reduce TB transmission
– Improve measurement of disease burden by effective surveillance,
monitoring and evaluation of TB programmes
– Ensure that countries have the capacity to perform TB-related
operational research to improve TB programme performance
6. Operational and public health research
– Improve TB case detection and diagnosis
– Investigate methods to improve access to treatment and treatment
delivery for drug-sensitive and drug-resistant TB
– Institute sustainable collaboration with all private and public
providers of TB care and control
– Address priority operational research questions at global, regional or
national level to improve implementation of collaborative TB and
HIV activities, and also in respect of other diseases or conditions in
which the risk for TB is increased
– Design collaborative activities in other disease programmes or
situations in which TB risk is increased
– Investigate methods to encourage community participation, to
increase the effectiveness of all interventions (e.g. case-finding,
access to treatment and care delivery)
– Optimize infection control to reduce TB transmission
– Improve measurement of disease burden by effective surveillance,
monitoring and evaluation of TB programmes
– Ensure that countries have the capacity to perform TB-related
operational research to improve TB programme performance
17. Five priority areas
1. Access, screening and
diagnosis of TB;
2. Sustainable collaboration with
all care-providers for TB
control;
3. Prevention of TB in people
living with HIV, and joint
treatment of HIV and TB;
4. Access to and delivery of
treatment for drug-susceptible
and M/XDR-TB;
5. Capacity-building for
operational research.
1. Access, screening and
diagnosis of TB;
2. Sustainable collaboration with
all care-providers for TB
control;
3. Prevention of TB in people
living with HIV, and joint
treatment of HIV and TB;
4. Access to and delivery of
treatment for drug-susceptible
and M/XDR-TB;
5. Capacity-building for
operational research.
18. KEY FACTS AND MESSAGES ON FUTURE TB RESEARCH
Global TB Report 2012 - WHO
• Develop new TB diagnostics, drugs, and vaccines
• WHO has endorsed several new diagnostic tests
or methods since 2007, including Xpert
MTB/RIF that has the potential to transform TB
care. Other new tests, including point- of- care
tests, are in development.
• 11 vaccine candidates for TB prevention in
Phase I or Phase II trials and one
immunotherapeutic vaccine in a Phase III trial. It
is hoped that one or two of the candidates in a
Phase II trial will enter a Phase III trial in the
next 2–3 years, with the possibility of licensing at
least one new vaccine by 2020.
• Develop new TB diagnostics, drugs, and vaccines
• WHO has endorsed several new diagnostic tests
or methods since 2007, including Xpert
MTB/RIF that has the potential to transform TB
care. Other new tests, including point- of- care
tests, are in development.
• 11 vaccine candidates for TB prevention in
Phase I or Phase II trials and one
immunotherapeutic vaccine in a Phase III trial. It
is hoped that one or two of the candidates in a
Phase II trial will enter a Phase III trial in the
next 2–3 years, with the possibility of licensing at
least one new vaccine by 2020.
19.
20. • 11 new or repurposed anti-TB drugs in clinical trials.
– Phase III trials of 4-month regimens for the treatment of drug-
susceptible TB are expected in 2013.
– 2 new compounds are being evaluated for use as an adjunct to
current optimized regimens for MDR-TB; one compound recently
moved to a Phase III trial and the other is expected to do so before
the end of 2012.
– A new three - drug combination regimen that could be used to
treat both drug-sensitive TB and MDR-TB and shorten
treatment duration has been tested in a Phase II study of early
bactericidal activity, with encouraging results.
• Funding for TB research and development has increased in
recent years, but stagnated between 2009 and 2010. At US$
630 million in 2010, funding falls far short of the annual
target of US$ 2 billion specified in the Global Plan to Stop
TB 2011–2015.
• 11 new or repurposed anti-TB drugs in clinical trials.
– Phase III trials of 4-month regimens for the treatment of drug-
susceptible TB are expected in 2013.
– 2 new compounds are being evaluated for use as an adjunct to
current optimized regimens for MDR-TB; one compound recently
moved to a Phase III trial and the other is expected to do so before
the end of 2012.
– A new three - drug combination regimen that could be used to
treat both drug-sensitive TB and MDR-TB and shorten
treatment duration has been tested in a Phase II study of early
bactericidal activity, with encouraging results.
• Funding for TB research and development has increased in
recent years, but stagnated between 2009 and 2010. At US$
630 million in 2010, funding falls far short of the annual
target of US$ 2 billion specified in the Global Plan to Stop
TB 2011–2015.
21. Lead Optimization
Preclinical
Development
GLP
Tox.
Phase I Phase II Phase III
Delamanid (OPC-67683)
Gatifloxacin
Moxifloxacin
Rifapentine
AZD5847
Bedaquiline (TMC-207)
Linezolid
Novel Regimens2
PA-824
Rifapentine
SQ-109
Sutezolid (PNU-100480)
CPZEN-45
DC-159a
Q201
SQ609
SQ641
Preclinical DevelopmentDiscovery1
Clinical Development
Diarylquinoline
DprE Inhibitors
GyrB inhibitors
InhA Inhibitors
LeuRS Inhibitors
MGyrX1 inhibitors
Mycobacterial Gyrase
Inhibitors
Pyrazinamide Analogs
Riminophenazines
Ruthenium (II) complexes
Spectinamides
Translocase-1 Inhibitors
Global TB Drug Pipeline
BTZ043
TBA-354
AZD5847
Bedaquiline (TMC-207)
Linezolid
Novel Regimens2
PA-824
Rifapentine
SQ-109
Sutezolid (PNU-100480)
CPZEN-45
DC-159a
Q201
SQ609
SQ641
Diarylquinoline
DprE Inhibitors
GyrB inhibitors
InhA Inhibitors
LeuRS Inhibitors
MGyrX1 inhibitors
Mycobacterial Gyrase
Inhibitors
Pyrazinamide Analogs
Riminophenazines
Ruthenium (II) complexes
Spectinamides
Translocase-1 Inhibitors
Chemical classes: fluoroquinolone, rifamycin, oxazolidinone, nitroimidazole, diarylquinoline, benzothiazinone
1 Ongoing projects without a lead compound series can be viewed at http://www.newtbdrugs.org/pipeline-discovery.php.
2 Combination regimens: first clinical trial (NC001) of a novel TB drug regimen testing the three drug combination of PA-824,
moxifloxacin, and pyrazinamide was initiated November 2010 and completed in 2011 with promising results. The second
clinical trial (NC002) of this regimen was launched in March 2012 and will test the efficacy of the regimen in drug-sensitive
and multidrug-resistant patients. The third clinical trial (NC003) will evaluate PA-824, TMC-207, pyrazinamide and
clofazimine in combinations and is scheduled to begin September 2012.
Updated: June 18, 2012
www.newtbdrugs.org
4 Repurposed Drugs
6 New Drugs
3 New Classes
Drugs currently in the regulatory
review process
Drugs currently in the regulatory
review process
24. Acknowledgements
• WHO/Stop TB Department:
• Diana Elizabeth Weil, Malgosia Grzemska, Mukund Waman Uplekar
and group for developing a New TB control Strategy post 2015
• Christian Lienhardt and GROUP in development of the “An
International Roadmap for Tuberculosis Research” and “Priorities
in Operational Research to Improve Tuberculosis Care and Control”
• WHO/WPRO: Catharina Van Weezenbeek
• NTP Viet Nam: Dinh Ngoc Sy and staff
• WHO/Stop TB Department:
• Diana Elizabeth Weil, Malgosia Grzemska, Mukund Waman Uplekar
and group for developing a New TB control Strategy post 2015
• Christian Lienhardt and GROUP in development of the “An
International Roadmap for Tuberculosis Research” and “Priorities
in Operational Research to Improve Tuberculosis Care and Control”
• WHO/WPRO: Catharina Van Weezenbeek
• NTP Viet Nam: Dinh Ngoc Sy and staff
25. Together
for a World free of TB !
THANKS YOU
FOR YOUR ATTENTION
vietnhung@yahoo.com